CME at Risk Dear Editor: Good issue! A couple of comments regarding your July/August editorial [“CME at Risk”]: Yes, at the moment, CME is at risk. Funding for CME is shifting perceptibly to promotional education, because, in pharmaceutical companies that have recently separated medical education from promotion, product managers are reluctant to “lose control” by assigning dollars to programs managed through scientific affairs or a similar department. You are optimistic when you suggest ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only gain access to Letters to the Editor, you'll get exclusive access to a large archive of premium content.

Already registered? here.